MBio Diagnostics landed a two-year, $1.4 million grant from the National Institute of Allergy and Infectious Diseases for the next development phase of a low-cost, point-of-care HIV antigen/antibody diagnostic test. Infectious disease specialists at the University of California, San Diego, are assisting with development. The company's pipeline includes diagnostics for tuberculosis and the hepatitis C virus.

Related Summaries